Very soon, I am going for surgical treatment for cancer. I wanted to use this opportunity to share my journey and advocate for prostate cancer screening for men. @prostatecanceruk.bsky.social prostatecanceruk.org/about-us/new...

Have we finally reached a turning point on prostate cancer screening?

After years of research and campaigning, we’re closer than ever to a prostate cancer screening programme. Here’s why 2025 could be the year things finally change.

prostatecanceruk.org

The latest from an honored member of the Royal Society. Every week he attacks the foundations of society in the UK and the EU and @royalsociety.org is apparently too worried about retribution to do anything about it.

Meet our Senior Director of Chemistry, Dr Andrea Testa, and discover his journey in targeted protein degradation research in this blog: trimtechtherapeutics.com/meet-the-tea...

Today's Bioorganic bingo 😂

In two important ways Labour empowered Nigel Farage and Faragism this week. Both were strategic mistakes. We’ve seen this story before. New writing from me. open.substack.com/pub/goodalla...

Labour seems determined to elevate Farage and Faragism- they should stop.

And why Starmer is "better"at foreign policy than domestic

open.substack.com

Not a bad commute to work.. 🚲

Nice timing to introduce @trimtech.bsky.social on this platform! Learn more about @trimtech.bsky.social foundational science here:

Zuzanna Kozicka@zkozicka.bsky.social · last yr.

Very excited for our next seminar this Thursday, March 20th: Martin Schwalm (@thesgc.bsky.social, formerly Knapp lab) will share insights on UPS inhibitors and Dean Clift (TRIMTECH Tx) will discuss hijacking TRIM21 for protein #degradation! 👉Join us at 12 PM EST/ 5 pm CET (‼️ US/EU time mismatch ‼️)

The first bifunctional protein degrader to deliver Phase III data! It seems to work, but people were definitely expecting more:

A Bifunctional Degrader Reads Out in Phase 3

science.org

And that's us! The news is out! #TRIMTECH

Rich Law@drrichjlaw.bsky.social · 2y ago

Lilly, Pfizer, & others, invest in Cambridge UK startup Trimtech Therapeutic's seed round for neurodegeneration protein degraders endpts.com/lilly-pfizer...

Really pleased to share this story from Amphista Therapeutics on the discovery and MoA of a potent and selective BRD9 "targeted glue" degrader. The compound also works in vivo and is orally bioavailable! Fantastic work from the team on a super fun project! www.biorxiv.org/content/10.1...

Wishing everyone a happy new year, pushing forward our science, hobbies and passions, surrounded by people we enjoy spending time with!

Amazing work!! Congratulations @alessiociulli.bsky.social and @alesalerno.bsky.social 💡🥂

Alessio Ciulli@alessiociulli.bsky.social · 2y ago

🚨 Exciting News! 🚨 What happens when unconventional ideas drive to push boundaries? 🚀 Meet FerroTACs: a novel #PROTAC design using ferrocene as core unit to re-imagining linker design and fine-tune their phys-chem properties. Learn more about our work led by @alesalerno.bsky.social here: 🧪👇 1/5

Happy to share our UBR4 structures. Check out the preprint to see how this giant E4 ligase complex selects substrates for ubiquitin chain extension. We also look at conservation and adaptations across humans, nematodes and plants. www.biorxiv.org/content/10.1... @clausenlab.bsky.social

Fantastic to see more ternary complex structures of #PROTACs recruiting novel E3 ligases!! www.nature.com/articles/s41...

Crystal structures of DCAF1-PROTAC-WDR5 ternary complexes provide insight into DCAF1 substrate specificity - Nature Communications

The authors show that DCAF1, a substrate receptor of CUL4 and EDVP E3 ligases, can be recruited by PROTACs to degrade the cancer drug target, WDR5. They also report the crystal structures of PROTAC te...

nature.com

Randomly meeting friends from #Dundee in Hong Kong airport 🥰🥰🥰

First post on here, on my way back from a fantastic #TPD conference in Shenzhen, China. Great science and a level of engagement well above expectations! Thanks for having me!!